OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook

OptimizeRx is upgraded to 'Buy' due to an improved 2027 growth outlook and an attractive valuation.

Q2 2026 saw gross margin rise to 76.5%, marking five consecutive quarters of gains amid a strategic shift to higher-margin offerings.

OPRX reaffirmed 2026 guidance: revenue of $95M–$100M and adjusted EBITDA of $21M–$25M.

Valuation remains compelling at 8.5x 2026E EPS and 7.2x 2027E EPS, with double-digit EPS growth expected in 2027.

I'm providing an update for OptimizeRx Corporation (OPRX), which I last wrote about in March 2026.

I had concerns back then that OPRX's lowered outlook for 2026 could